Trial Profile

Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorinostat (Primary)
Indications Cutaneous T-cell lymphoma
Focus Adverse reactions
Sponsors Merck Sharp & Dohme

Most Recent Events

03 Jul 2012 Actual end date changed from Jun 2011 to Jul 2011 as reported by ClinicalTrials.gov.
03 Jul 2012 Actual patient number is 10 according to ClinicalTrials.gov.
11 Aug 2011 Actual end date changed from Sep 2011 to Jun 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com